Article
5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.
Anti-cancer drugs - 1 Mar 2017
Onesti Concetta E, Botticelli Andrea, La Torre Marco, Borro Marina, Gentile Giovanna, Romiti Adriana, Lionetto Luana, Petremolo Antonella, Occhipinti Mario, Roberto Michela, Falcone Rosa, Simmaco Maurizio, Marchetti Paolo, Mazzuca Federica
Abstract excerpt
5-Fluorouracil is commonly used for gastrointestinal cancer treatment in an adjuvant setting; however, the toxicity can lead to a reduction, delay, or discontinuation of treatment. We retrospectively investigated the association between the 5-fluorouracil degradation rate (5-FUDR) and genetic polymorphisms of TSER, DPYD, and MHTFR with toxicity in colorectal cancer patients treated with adjuvant FOLFOX....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
